NanoViricides is trading 6.6% up at $1.45 after receiving Democratic Republic of Congo regulatory approval on August 10, 2026, to begin a Phase II trial of NV-387 oral gummies for Bundibugyo Ebola and other Ebola viruses.
- Patient treatment is expected to begin soon; clinical supplies have already been delivered, with Om Sai Clinical Research overseeing operations.
- Broader markets are modestly higher ahead of CPI, but the company-specific approval is the clearer catalyst.